Synthesis of novel gallium-68 labeled rhodamine: A potential PET myocardial perfusion agent

A new determination of the 68Ga half-life and evaluation of literature data

Inconsistencies within the 68Ga half-life dataset have been repeatedly identified in nuclear decay data evaluations performed over the past decade. In this paper, a half-life has been determined using ionisation chambers measurements and HPGe gamma-ray spectrometry (T1/2 = 67.783(27) min). The current literature has been reviewed and possible causes of discrepancy have been identified, such as neglected contaminant effects, robustness of analysis, and underestimation of systematic effects. This could lead to a significant improvement of the half-life in future evaluations.

On Cyclotron-Based Production of Gallium-68 Isotope: A Computational Benchmark for the Production Yield & Shielding Considerations

Gallium-68 (68Ga) has played a relevant role for the novel studies in the nuclear medicine area. Its production has been made traditionally and initially using 68Ge/68Ga generators. These devices represent some flaws, namely, high costs, low activity per elution, and long-time waiting between elutions. In order to address these concerns, the cyclotron-based production of 68Ga has been recently investigated and has shown promising outcomes regarding the activity at the end of bombardment for both solid and liquid targets. Currently, the use of computational codes and theoretical calculations takes relevance when it comes to calculating relevant nuclear physics quantities such as the production yield and the ambient dose rate. These outcomes are important for having a proper understanding of all the reactions involved during an irradiation routine with protons on a target. In this work, we used important cad-based programs, Monte Carlo codes, and a deterministic calculator with the objective of making a full benchmark with a previous experimental research. We also calculated the shielding requirements for this kind of isotope production facility. The proposed shielding materials and their respective thickness showed to be sufficient to avoid high ambient dose rates outside the machine. For the production yield, we found out that a hybrid combination of Monte Carlo codes and subsequently a computation with a deterministic calculator gave us more precise results for the irradiation conditions considered here.

Development of new copper-64 labeled rhodamine: a potential PET myocardial perfusion imaging agent

Background

Myocardial perfusion imaging (MPI) is one of the most commonly performed investigations in nuclear medicine procedures. Due to the longer half-life of the emerging positron emitter copper-64 and its availability from low energy cyclotron, together with its well-known coordination chemistry, we have synthesized ⁶⁴Cu-labeled NOTA- and ⁶⁴Cu-NOTAM-rhodamine conjugates as potential cardiac imaging agents using PET.

Results

⁶⁴Cu-NOTA- and ⁶⁴Cu-NOTAM-rhodamine conjugates were synthesized using a traightforward and one-step simple reaction. Radiochemical yields were greater than 97% (decay corrected), with a total synthesis time of less than 25 min. Radiochemical purities were always greater than 98% as assessed by TLC and HPLC. These synthetic approaches hold considerable promise as a simple method for ⁶⁴Cu-rhodamine conjugates synthesis, with high radiochemical yield and purity. Biodistribution studies in normal Fischer rats at 60 min post-injection, demonstrated significant heart uptake and a good biodistribution profile for both the radioconjugates. However, the ⁶⁴Cu-NOTAM-rhodamine conjugate has shown more heart uptake (~ 10% ID/g) over the ⁶⁴Cu-NOTA-rhodamine conjugate (5.6% ID/g).

Conclusions

These results demonstrate that these radioconjugates may be useful probes for the PET evaluation of MPI.

Novel Tracers and Radionuclides in PET Imaging

The use of PET imaging agents in oncology, cardiovascular disease, and neurodegenerative disease shows the power of this technique in evaluating the molecular and biological characteristics of numerous diseases. These agents provide crucial information for designing therapeutic strategies for individual patients. Novel PET tracers are in continual development and many have potential use in clinical and research settings. This article discusses the potential applications of tracers in diagnostics, the biological characteristics of diseases, the ability to provide prognostic indicators, and using this information to guide treatment strategies including monitoring treatment efficacy in real time to improve outcomes and survival.